HSD11B1 and renal carcinoma: In conclusion, this work supports the hypothesis that the combination of an HSD11B1 inhibitor with immune checkpoint blockade may be beneficial in renal cancer patients, highlighting the role of endogenous glucocorticoid metabolism in the efficacy of immunotherapy.